Sean McWhinney1, Marian Kolenic2,3, Katja Franke4, Marketa Fialova2, Pavel Knytl2, Martin Matejka2,3, Filip Spaniel2,3, Tomas Hajek1,2. 1. Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada. 2. National Institute of Mental Health, Klecany, Czech Republic. 3. Third Faculty of Medicine, Charles University, Prague, Czech Republic. 4. Structural Brain Mapping Group, Department of Neurology, Jena University Hospital, Jena, Germany.
Abstract
BACKGROUND: Obesity is highly prevalent in schizophrenia, with implications for psychiatric prognosis, possibly through links between obesity and brain structure. In this longitudinal study in first episode of psychosis (FEP), we used machine learning and structural magnetic resonance imaging (MRI) to study the impact of psychotic illness and obesity on brain ageing/neuroprogression shortly after illness onset. METHODS: We acquired 2 prospective MRI scans on average 1.61 years apart in 183 FEP and 155 control individuals. We used a machine learning model trained on an independent sample of 504 controls to estimate the individual brain ages of study participants and calculated BrainAGE by subtracting chronological from the estimated brain age. RESULTS: Individuals with FEP had a higher initial BrainAGE than controls (3.39 ± 6.36 vs 1.72 ± 5.56 years; β = 1.68, t(336) = 2.59, P = .01), but similar annual rates of brain ageing over time (1.28 ± 2.40 vs 1.07±1.74 estimated years/actual year; t(333) = 0.93, P = .18). Across both cohorts, greater baseline body mass index (BMI) predicted faster brain ageing (β = 0.08, t(333) = 2.59, P = .01). For each additional BMI point, the brain aged by an additional month per year. Worsening of functioning over time (Global Assessment of Functioning; β = -0.04, t(164) = -2.48, P = .01) and increases especially in negative symptoms on the Positive and Negative Syndrome Scale (β = 0.11, t(175) = 3.11, P = .002) were associated with faster brain ageing in FEP. CONCLUSIONS: Brain alterations in psychosis are manifest already during the first episode and over time get worse in those with worsening clinical outcomes or higher baseline BMI. As baseline BMI predicted faster brain ageing, obesity may represent a modifiable risk factor in FEP that is linked with psychiatric outcomes via effects on brain structure.
BACKGROUND: Obesity is highly prevalent in schizophrenia, with implications for psychiatric prognosis, possibly through links between obesity and brain structure. In this longitudinal study in first episode of psychosis (FEP), we used machine learning and structural magnetic resonance imaging (MRI) to study the impact of psychotic illness and obesity on brain ageing/neuroprogression shortly after illness onset. METHODS: We acquired 2 prospective MRI scans on average 1.61 years apart in 183 FEP and 155 control individuals. We used a machine learning model trained on an independent sample of 504 controls to estimate the individual brain ages of study participants and calculated BrainAGE by subtracting chronological from the estimated brain age. RESULTS: Individuals with FEP had a higher initial BrainAGE than controls (3.39 ± 6.36 vs 1.72 ± 5.56 years; β = 1.68, t(336) = 2.59, P = .01), but similar annual rates of brain ageing over time (1.28 ± 2.40 vs 1.07±1.74 estimated years/actual year; t(333) = 0.93, P = .18). Across both cohorts, greater baseline body mass index (BMI) predicted faster brain ageing (β = 0.08, t(333) = 2.59, P = .01). For each additional BMI point, the brain aged by an additional month per year. Worsening of functioning over time (Global Assessment of Functioning; β = -0.04, t(164) = -2.48, P = .01) and increases especially in negative symptoms on the Positive and Negative Syndrome Scale (β = 0.11, t(175) = 3.11, P = .002) were associated with faster brain ageing in FEP. CONCLUSIONS: Brain alterations in psychosis are manifest already during the first episode and over time get worse in those with worsening clinical outcomes or higher baseline BMI. As baseline BMI predicted faster brain ageing, obesity may represent a modifiable risk factor in FEP that is linked with psychiatric outcomes via effects on brain structure.
Authors: Robyn A Honea; Amanda N Szabo-Reed; Rebecca J Lepping; Rodrigo Perea; Florence Breslin; Laura E Martin; William M Brooks; Joseph E Donnelly; Cary R Savage Journal: Obesity (Silver Spring) Date: 2016-07-19 Impact factor: 5.002
Authors: Luca De Peri; Alessandra Crescini; Giacomo Deste; Paolo Fusar-Poli; Emilio Sacchetti; Antonio Vita Journal: Curr Pharm Des Date: 2012 Impact factor: 3.116
Authors: Davy Vancampfort; Brendon Stubbs; Alex J Mitchell; Marc De Hert; Martien Wampers; Philip B Ward; Simon Rosenbaum; Christoph U Correll Journal: World Psychiatry Date: 2015-10 Impact factor: 49.548
Authors: Trang T Le; Rayus T Kuplicki; Brett A McKinney; Hung-Wen Yeh; Wesley K Thompson; Martin P Paulus Journal: Front Aging Neurosci Date: 2018-10-24 Impact factor: 5.750
Authors: Juha Veijola; Joyce Y Guo; Jani S Moilanen; Erika Jääskeläinen; Jouko Miettunen; Merja Kyllönen; Marianne Haapea; Sanna Huhtaniska; Antti Alaräisänen; Pirjo Mäki; Vesa Kiviniemi; Juha Nikkinen; Tuomo Starck; Jukka J Remes; Päivikki Tanskanen; Osmo Tervonen; Alle-Meije Wink; Angie Kehagia; John Suckling; Hiroyuki Kobayashi; Jennifer H Barnett; Anna Barnes; Hannu J Koponen; Peter B Jones; Matti Isohanni; Graham K Murray Journal: PLoS One Date: 2014-07-18 Impact factor: 3.240
Authors: Lisa Ronan; Aaron F Alexander-Bloch; Konrad Wagstyl; Sadaf Farooqi; Carol Brayne; Lorraine K Tyler; Paul C Fletcher Journal: Neurobiol Aging Date: 2016-07-27 Impact factor: 4.673
Authors: Shalaila S Haas; Ruiyang Ge; Nicole Sanford; Amirhossein Modabbernia; Abraham Reichenberg; Heather C Whalley; René S Kahn; Sophia Frangou Journal: Front Psychiatry Date: 2022-06-22 Impact factor: 5.435
Authors: Sean R McWhinney; Christoph Abé; Martin Alda; Francesco Benedetti; Erlend Bøen; Caterina Del Mar Bonnin; Tiana Borgers; Katharina Brosch; Erick J Canales-Rodríguez; Dara M Cannon; Udo Dannlowski; Ana M Diaz-Zuluaga; Lorielle Dietze; Torbjørn Elvsåshagen; Lisa T Eyler; Janice M Fullerton; Jose M Goikolea; Janik Goltermann; Dominik Grotegerd; Bartholomeus C M Haarman; Tim Hahn; Fleur M Howells; Martin Ingvar; Tilo T J Kircher; Axel Krug; Rayus T Kuplicki; Mikael Landén; Hannah Lemke; Benny Liberg; Carlos Lopez-Jaramillo; Ulrik F Malt; Fiona M Martyn; Elena Mazza; Colm McDonald; Genevieve McPhilemy; Sandra Meier; Susanne Meinert; Tina Meller; Elisa M T Melloni; Philip B Mitchell; Leila Nabulsi; Igor Nenadic; Nils Opel; Roel A Ophoff; Bronwyn J Overs; Julia-Katharina Pfarr; Julian A Pineda-Zapata; Edith Pomarol-Clotet; Joaquim Raduà; Jonathan Repple; Maike Richter; Kai G Ringwald; Gloria Roberts; Alex Ross; Raymond Salvador; Jonathan Savitz; Simon Schmitt; Peter R Schofield; Kang Sim; Dan J Stein; Frederike Stein; Henk S Temmingh; Katharina Thiel; Sophia I Thomopoulos; Neeltje E M van Haren; Holly Van Gestel; Cristian Vargas; Eduard Vieta; Annabel Vreeker; Lena Waltemate; Lakshmi N Yatham; Christopher R K Ching; Ole A Andreassen; Paul M Thompson; Tomas Hajek Journal: Bipolar Disord Date: 2021-12-16 Impact factor: 5.345
Authors: Dan Siskind; Anthony W Russell; Shuichi Suetani; Dylan Flaws; Steve Kisely; Vikas Moudgil; Korinne Northwood; Gail Robinson; James G Scott; Terry Stedman; Nicola Warren; Karl Winckel; Peter Cosgrove; Andrea Baker Journal: Ther Adv Psychopharmacol Date: 2021-10-16
Authors: Jo Wrigglesworth; Ian H Harding; Phillip Ward; Robyn L Woods; Elsdon Storey; Bernadette Fitzgibbon; Gary Egan; Anne Murray; Raj C Shah; Ruth E Trevaks; Stephanie Ward; John J McNeil; Joanne Ryan Journal: J Alzheimers Dis Rep Date: 2022-04-04